JNJ241220C162500
- 0.01
- 0.000.00%
Johnson & Johnson Newsroom
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
These Are the Best and Worst Stocks This Year
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Investors in Johnson & Johnson (NYSE:JNJ) Have Unfortunately Lost 8.8% Over the Last Three Years
Is Johnson & Johnson (JNJ) the Best Pharma Dividend Stock to Buy In 2024?
Dow's Nearly 225-Point Drop Led By Losses In Nike, Boeing Stocks
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
J&J Trading Near 52-Week Low: Should You Sell the Stock?
Johnson & Johnson (JNJ.US) has introduced Kaken's preclinical STAT6 inhibitor.
Kaken will receive a prepayment of 30 million dollars from Johnson & Johnson (JNJ.US), as well as subsequent payments of up to 1.2175 billion dollars based on development progress and sales milestones.
Express News | J&J: Ec Approves Rybrevant in Combination With Lazcluze for First-Line Treatment of Patients With Egfr-Mutated Advanced Non-Small Cell Lung Cancer
J&J Unit's Rybrevant Combo Gains EU Nod for Type 2 Indication Expansion
Johnson & Johnson (NYSE:JNJ) Seems To Use Debt Quite Sensibly
Weekly Buzz: So far, Santa is Letting us Down
Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723
Sector Update: Health Care Stocks Edge Up in Afternoon Trading
FDA Proposes Testing Talc Products for Asbestos: Report
Johnson & Johnson Signs Licensing Deal for Kaken's Program for Autoimmune, Allergic Diseases
Johnson & Johnson (JNJ) Is Attracting Investor Attention: Here Is What You Should Know